Mesenchymal stem cells (MSCs) have been shown to have beneficial effects in the treatment of congestive heart failure (CHF) through multiple mechanisms:
Anti-inflammatory effects: MSCs have immunomodulatory properties and can reduce inflammation in the heart, which is a key contributor to CHF. They can also reduce oxidative stress and prevent cell death.
Promotion of tissue repair: MSCs can guide various types of cardiovascular cells to promote angiogenesis and guide the formation of new blood vessels.
Improvement of cardiac function: MSCs can increase cardiac output and improve left ventricular function in patients with CHF.
Reduction of fibrosis: MSCs can reduce fibrosis or scarring in the heart, which is a common consequence of CHF.
Overall, MSCs have the potential to address multiple aspects of CHF and are probably the best treatment option available.
